Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Recent evidence has indicated that type 2 diabetes mellitus (T2DM) increases the risk of developing Alzheimer's disease (AD). Therefore, it is crucial to investigate the potential common processes that could explain this relation between AD and T2DM. In the recent decades, an abundance of evidence has emerged demonstrating that chronic inflammatory processes may be the major factors contributing to the development and progression of T2DM and AD. In this article, we have discussed the molecular underpinnings of inflammatory process that contribute to the pathogenesis of T2DM and AD and how they are linked to these two diseases. In depth understanding of the inflammatory mechanisms through which AD and T2DM are associated to each other may help the researchers to develop novel and more effective strategies to treat together AD and T2DM. Several treatment options have been identified which spurn the inflammatory processes and discourage the production of inflammatory mediators, thereby preventing or slowing down the onset of T2DM and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Several clinical studies have demonstrated the pivotal role of insulin resistance and dysfunctional insulin signaling in the brain in the pathogenesis of AD (Gasparini et al., 2002; Steen et al., 2005; Ho et al., 2004; Aliev et al., 2014).”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“When microglia in the brain attack and engulf foreign substances, they release cytokines, chemokines, enzymes, growth factors and reactive oxygen species similar to the ones produced by the macrophages found in the peripheral parts of the body (McGeer and McGeer, 1995).”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Chronic stress and age-related increases in the proinflammatory cytokine IL-6.
Kiecolt-Glaser, J. K., Preacher, K. J., MacCallum, R. C., Atkinson, C., Malarkey, W. B., & Glaser, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1531903100 · Cited by 1,267
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 1×
“The greatest risk reduction to develop AD was seen among those with extended exposure to NSAIDs (In’t Veld et al., 2001; Zandi et al., 2002; Aisen et al., 2002).”
NF-kB: a crucial transcription factor for glial and neuronal cell function
O'Neill, L. A. J., & Kaltschmidt, C. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01035-1 · Cited by 1,013 · cited 1×
“Recent findings have shown the involvement of NFjB in brain processes, especially in neurodegenerative diseases such as AD (O’Neill and Kaltschmidt, 1997).”
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664 · cited 1×
“…in press as: Mushtaq, G. et al., Alzheimer’s disease an of Biological Sciences (2014), http://dx.doi.org/10.1016/j.sjbs.2014.05.003 factors from T2DM could leak to the brain parenchyma and induce the activation of microglial cells to release inflammatory molecules in the brain (Breteler, 2000).”
InfluentialAge-related inflammatory cytokines and disease
Brüünsgaard, H., & Pedersen, B. K. (2003) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(02)00056-5 · Cited by 608 · cited 1×
“Higher levels of TNF-a were also detected in the cerebrospinal fluid (CSF), cortex and glial cells of elderly patients suffering from AD suggesting a direct role TNF-a seems to play in the pathogenesis of T2DM and AD in the elderly (Bruunsgaard and Pedersen, 2003).”
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 2×
“…another study conducted on systemic LPS inflammation model in mice that two day-intraperitoneal injection of liraglutide resulted in noticeable reduction of proinflammatory cytokines and enhanced anti-inflammatory cytokines in the blood, spleen and brains of those mice (Hunter and Holscher, 2012).”
BackgroundResultCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Sheng, J. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00069-x · Cited by 388 · cited 1×
“Increased APP expression and enhanced accumulation of Ab due to experimental neuroinflammation were demonstrated in this study (Sheng et al., 2003).”
BackgroundEfficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Townsend, M., Mehta, T., & Selkoe, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610390200 · Cited by 318 · cited 1×
“By interfering with insulin receptor function in the neurons, Ab prevents the rapid activation of certain kinases which are essential for long term potentiation (Xie et al., 2002; Townsend et al., 2007).”
BackgroundGlucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 1×
“In addition to GLP-1’s anti-inflammatory role in the treatment of T2DM, in vitro studies have provided evidence that GLP-1 may be a modulator of inflammation in the central nervous system due to its direct role in reducing cytokine release (Iwai et al., 2006).”
Seufert, J., Kieffer, T. J., & Habener, J. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.674 · Cited by 193 · cited 1×
“It has been shown that leptin exerts inhibitory effects on insulin gene expression as well as insulin secretion from pancreatic b-cells (Seufert et al., 1999).”
BackgroundYamamoto, M., Kiyota, T., Walsh, S. M., Liu, J., Kipnis, J., & Ikezu, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3877 · Cited by 100 · cited 2×
“…on cultured human monocyte-derived macrophages suggest that pro-inflammatory cytokines reduce the expression of insulin degrading enzyme (IDE) and suppress Ab degradation as well as its subsequent clearance in the brain (Yamamoto et al., 2008). d type 2 diabetes via chronic inflammatory mechanisms.”
Background
Cited by
Mushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023141545 · Cited by 331
Self-citationThe role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Medicinal properties of mangosteen (Garcinia mangostana L.): A comprehensive update
Ovalle-Magallanes, B., Eugenio-Pérez, D., & Pedraza-Chaverri, J. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.08.021 · Cited by 260
Muzambi, R., Bhaskaran, K., Smeeth, L., Brayne, C., Chaturvedi, N., & Warren-Gash, C. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00118-5 · Cited by 84
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
Metadata
- Authors
- Mushtaq, G., Khan, J. A., Kumosani, T. A., & Kamal, M. A.
- Venue
- Saudi Journal of Biological Sciences
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 22
- Issue
- 1
- Pages
- 4-13
- ISSN
- 1319-562X (ISSN-L)
- OpenAlex
- W2022709952
- Cited by
- 71
- References
- 28
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.